Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may unmask Alzheimer's during hospital stays

NCT ID NCT07222280

Diagnosis Sponsor: Covenant Health, US Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a blood test (Quest AD-Detect) can help doctors identify Alzheimer's disease earlier in patients aged 60-90 who are hospitalized with confusion or delirium. The test looks for a protein linked to Alzheimer's. Patients with positive results will get follow-up care to confirm the diagnosis. The goal is to speed up detection and treatment for those with underlying Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 60 to 90 years old * No prior diagnosis of dementia * Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state Exclusion Criteria: * Age under 60 years * Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer dementia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease brain disorder cognitive disorder Confusion delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer dementia Alzheimer disease Cognitive abnormality Delirium confusional state Encephalopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cumberland Medical Center

    RECRUITING

    Crossville, Tennessee, 38555, United States

  • Fort Loudon Medical Center

    RECRUITING

    Lenoir City, Tennessee, 37772, United States

  • Fort Sanders Regional Medical Center

    RECRUITING

    Knoxville, Tennessee, 37916, United States

  • LeConte Medical Center

    RECRUITING

    Sevierville, Tennessee, 37862, United States

  • Methodist Medical Center

    RECRUITING

    Oak Ridge, Tennessee, 37830, United States

  • Roane Medical Center

    RECRUITING

    Harriman, Tennessee, 37748, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.